Home > News > Industry News
Back >>

CIC summit was held in Nanjing

Release date:2014-11-12Collect

          January 9th -11th, 2014, CIC's annual summit was held in Jiangsu Province, a conference center,healthcare professionals, policy makers, industry representatives and investor from around the world gathered to discuss the "translational medicine" in China  Innovation in Cardiovascular, to discuss the clinical needs of patients in China, and these requirements into clinical products, and finally realize the benefit of the patient in mind. This echoes the essence of having a market value of the product, the ultimate benefit of patients has been advocated by the Translational Medicine will translate into clinical concepts.

CIC's first summit in 2014, by the Chinese Medical Society of Cardiology (CSC) and the Medical Society of Electrophysiology and Pacing Branch (CSPE) organized the First Affiliated Hospital of Nanjing Medical University, contractors, DiNova Capital, first-Technology, and Medtronic co. Five sponsors inaugural summit include: Professor Yong Huo (Chinese Medical Society of Cardiology, Chairman and CIC Summit Chair), Professor Zhang Shu (Medical Society of Electrophysiology and Pacing Session Chair and Chief CIC Summit Chairman), Kong Xiangqing Professor (Nanjing Medical University First Affiliated hospital, director of cardiology and chief CIC Summit Executive Chairman), Mr. Zi Zhenjun (DiNova Capital partner and Executive Chairman of the Joint Summit CIC); Mr. Zhao Yiwei (LIFETECH Technology CEO and Executive Chairman of the Joint Summit CIC) .

       In the three-day summit, academic leaders from government, the medical profession, medical innovation and enterprise, elite investors in the form of round-table discussions on today's hottest areas of cardiovascular transcatheter aortic valve implantation (TAVI) , transcatheter pulmonary valve implantation (PAVI), a new treatment of atrial fibrillation (A Fib), left atrial appendage occlusion (LAA) and other 10 topics 2 hours group discussion, each participant select five interest issues involved in the discussion, each table has a chief expert as a speaker and moderator. Moderator introduces the latest technology for a specific disease, therapy and vision, and as a background discussion. Then, the host for this case, combined with the specific circumstances of Chinese patients and industry, and guide you to do in-depth discussion. Guests and participate in the discussion academic leaders, industry experts and other participants in-depth communication, share their views, challenge traditional ideas, explore new ideas. This form of debate and brainstorming greatly encourage innovation, build consensus, clear direction, the patient did not find better treatment options.

       After the meeting, CIC summit organizers will discuss the results and apply it to track potential research programs and product development, hoping to create opportunities for the participants of the subsequent cooperative clinical experts, industry and the investment community to discuss the essence of the summit to explore common industrialization possible.

       Summit organizers, the summit's mission is: to help clinical experts, government officials, business representatives and investors to build a platform for mutual exchange, we go through this platform collaborative research, co-development, co-transformation of the patient's clinical suit the needs of China products. Hope that through the annual summit and other publicity channels CIC's ability to attract and motivate as many stakeholders to participate in this project. This will greatly promote China's cutting-edge medical research, innovation and product development, development of medical and industrial competitiveness, innovation, investment, and optimize patient care and other areas. Organizers believe the CIC's annual summit will become a milestone of great historical significance, it brings together the strengths of all the clinical concept transformed into medical applications, and to indicate the direction for China's medical industry, opening up ideas, to lay the foundation, ultimately promote the improvement of China cardiovascular disease treatment technology.